Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of this trial is to compare two NN1250 (insulin degludec) formulations with each other and with insulin glargine, all in combination with insulin aspart in subjects with type 1 diabetes.

Official Title
-----------------
A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 1

Intervention / Treatment
-----------------
* Drug: insulin degludec
* Drug: insulin degludec
* Drug: insulin glargine
* Drug: insulin aspart


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 1 diabetes for at least one year HbA1c 7-11% (both inclusive) Treated with insulin for at least six months - any regimen Exclusion Criteria: Any systemic treatment with products which in the Investigator's opinion could interfere with glucose or lipid metabolism (eg systemic corticosteroids) 3 months prior to randomisation Subject has a clinically significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, neurological, genitourinary, or haematological system that, in the opinion of the Investigator, may confound the results of the trial or pose additional risk in administering trial product

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SIBA (D)<br> | Drug: insulin degludec<br>* Formulation 1: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily<br>Drug: insulin aspart<br>* Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily<br>|
| Experimental: SIBA (E)<br> | Drug: insulin degludec<br>* Formulation 2: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily<br>Drug: insulin aspart<br>* Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily<br>|
| Experimental: IGlar<br> | Drug: insulin glargine<br>* Treat-to-target dose titration scheme, injection s.c., once daily<br>Drug: insulin aspart<br>* Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Glycosylated Haemoglobin (HbA1c) | Change from baseline in HbA1c after 16 weeks of treatment | Week 0, Week 16 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Fasting Plasma Glucose (FPG) | Change from baseline in FPG (expressed in mmol/L, 1 mg/dL = 18times mmol/L) after 16 weeks of treatment | Week 0, Week 16 | 
| Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) | Estimate of the overall mean of SMPG (expressed in mmol/L, 1 mg/dL = 18times mmol/L) after 16 weeks of treatment. Plasma glucose measured: before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, bedtime, at 4 am and before breakfast. | Week 16 | 
| Rate of Major and Minor Hypoglycaemic Episodes | Rate of major and minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. | Week 0 to Week 16 + 5 days follow up | 
| Rate of Nocturnal Major and Minor Hypoglycaemic Episodes | Rate of nocturnal major and minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Episodes were defined as nocturnal if the time of onset was between 23:00 (included) and 06:00 (excluded). | Week 0 to Week 16 + 5 days follow up | 
| Rate of Treatment Emergent Adverse Events (AEs) | Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect. | Week 0 to Week 16 + 5 days follow up | 
| Laboratory Safety Parameters (Biochemistry): Alanine Aminotransferase (ALAT) | Laboratory values at screening (Week -1) and at Week 16 | Week -1, Week 16 | 
| Laboratory Safety Parameters (Biochemistry): Aspartate Aminotransferase (ASAT) | Laboratory values at screening (Week -1) and at Week 16 | Week -1, Week 16 | 
| Laboratory Safety Parameters (Biochemistry): Serum Creatinine | Laboratory values at screening (Week -1) and at Week 16 | Week -1, Week 16 | 
| Vital Signs: Diastolic BP (Blood Pressure) | Values at baseline (Week 0) and at Week 16 | Week 0, Week 16 | 
| Vital Signs: Systolic BP (Blood Pressure) | Values at baseline (Week 0) and at Week 16 | Week 0, Week 16 | 
| Vital Signs: Pulse | Values at baseline (Week 0) and at Week 16 | Week 0, Week 16 | 
| Physical Examination | Physical examination was performed at screening (week -1), and after 8 and 16 weeks of treatment. If any new findings or deterioration in previous findings were observed during the trial, these were recorded as AEs and are therefore not presented separately as no analysis was performed. | Week -1, Week 8, Week 16 |